The advice biotech founders get about LinkedIn thought leadership is mostly wrong. "Post daily." "Comment on 20 posts a day." "Use hooks, lists, controversy." All of this is generic SaaS advice repackaged for biotech — and it produces the kind of generic content that actively damages a scientist's credibility.
Real thought leadership for biotech founders looks completely different. Here's what actually works.
The core insight: scientists are trusted, marketers are not
The reason "growth hacker" tactics fail for biotech founders is that biotech audiences — investors, KOLs, scientists, BD teams — are unusually allergic to performance. They've spent careers training to detect bullshit. Performative content reads as bullshit. Quiet, substantive content reads as credible.
Your goal isn't to perform expertise. It's to demonstrate it through the substance of what you say.
The myth of daily posting
Daily posting works for marketers selling to marketers. It does not work for biotech founders. Here's why:
- You don't have a daily insight worth sharing. Almost no one does.
- Daily content drops in quality. Audiences notice.
- The signal you send is "I have time to do this all day" — which to a serious investor or pharma BD exec, means "I'm not running a real company."
The right cadence for thought leadership is quality-bound, not frequency-bound. Post when you have something defensible to say. Stay quiet otherwise.
The four-week thought leadership rhythm
The system we use with biotech founders looks like this. Four-week repeating cycle:
Week 1: One scientific perspective
A substantive take on something happening in your scientific field. New paper, new clinical readout, new approach. Your job: interpret it through your lens. Not "here's a paper" — but "here's why this changes how I think about [problem]."
Week 2: One founder lesson
Something you learned the hard way running the company. Honest, specific, useful to other founders. This is what humanizes you and builds the parasocial trust that warms up later conversations.
Week 3: One industry observation
Your view on a broader trend in biotech — funding patterns, M&A activity, regulatory shifts. The interpretation is the value, not the news itself.
Week 4: One useful artifact
A teardown, framework, mental model, or breakdown that's useful even if no one knows you. The post that gets shared by people who'd never otherwise share you.
That's four posts a month. Sixteen a quarter. Sixty-four in a year. Done well, that's enough to dominate the conversation in any biotech sub-category.
Thought leadership isn't built by posting more. It's built by being right, repeatedly, in public.
What gets people to actually read your posts
Three things, in order of importance:
- Specificity. Specific examples, specific numbers, specific opinions. Vague costs you trust.
- Honest stakes. Posts that say "I was wrong about X" or "this scared us" outperform posts that say "I'm crushing it."
- A clear single idea. One argument per post. Not five tips. Not seven things. One claim, defended well.
Engagement is a downstream metric, not an upstream goal
Don't optimize for likes. Don't write for "the algorithm." Write for the five people you most want to read this — your dream investor, the BD lead at the pharma company you want as a partner, the scientist you want to recruit. If those five people would respect this post, ship it. If they'd cringe, kill it.
Counterintuitively, this is the strategy that actually builds reach. The algorithm rewards the engagement that comes from substantive readers. The "growth hack" content gets bot engagement that goes nowhere.
The 12-month outcome
Founders who run this rhythm for a year — disciplined, no shortcuts — consistently see:
- Recognition from investors before any meeting takes place
- Inbound from pharma BD teams asking to talk
- Conference invitations they used to chase
- Job applications from senior scientists at top labs
None of this requires posting daily. None of it requires becoming a content creator. It requires four good posts a month, sustained, for twelve months. That's the entire game.